Data layers Raw facts Calculated Model prediction AI interpretation

Cross-Market Price Comparison

Other Listed Market Shenzhen (SZSE) — 康龙化成
Other Market Stock Code300759
H-Share Offer PriceTo be extracted
Other Market PriceLoading...
Reference Exchange RateLoading...
H-Share Offer Price Premium/Discount vs Other MarketLoading...

Company Overview

Stock NamePharmaron
Stock Code03759
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities領先的全流程一體化醫藥研發服務平台,提供藥物發現、臨床前及早期臨床開發服務,並拓展下游臨床後期開發及商業化生產等服務。
Listing Date2019-11-28
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國北京經濟技術開發區泰河路6號1幢8層
Business Address (Hong Kong)香港灣仔皇后大道東248號陽光中心40樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitepharmaron.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingYes (A股)

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 39.50 / shares
Offer Price RangeTo be extracted
Lot Size100 shares
Entry ThresholdTo be extracted
Par ValueRMB 1.0 / shares
Offer Period2019-11-14 to 2019-11-20
Global Offering Shares116,536,100 shares
HK Public Offer Shares (Initial)11,653,700 shares (10.0%)
Public Offer Lots (Initial)116,537lots (Pool A58,268lots,Pool B58,269lots)
International Placing Shares (Initial)104,882,400 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO776,907,062 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share27.2%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 4,603,175,950

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 100 HK$ 3,950
2 lots 200 HK$ 7,900
3 lots 300 HK$ 11,850
4 lots 400 HK$ 15,800
5 lots 500 HK$ 19,750
6 lots 600 HK$ 23,700
7 lots 700 HK$ 27,650
8 lots 800 HK$ 31,600
9 lots 900 HK$ 35,550
10 lots 1,000 HK$ 39,500
15 lots 1,500 HK$ 59,250
20 lots 2,000 HK$ 79,000
25 lots 2,500 HK$ 98,750
30 lots 3,000 HK$ 118,500
35 lots 3,500 HK$ 138,250
40 lots 4,000 HK$ 158,000
45 lots 4,500 HK$ 177,750
50 lots 5,000 HK$ 197,500
60 lots 6,000 HK$ 237,000
70 lots 7,000 HK$ 276,500
80 lots 8,000 HK$ 316,000
90 lots 9,000 HK$ 355,500
100 lots 10,000 HK$ 395,000
200 lots 20,000 HK$ 790,000
300 lots 30,000 HK$ 1,185,000
400 lots 40,000 HK$ 1,580,000
500 lots 50,000 HK$ 1,975,000
600 lots 60,000 HK$ 2,370,000
700 lots 70,000 HK$ 2,765,000
800 lots 80,000 HK$ 3,160,000
900 lots 90,000 HK$ 3,555,000
1,000 lots 100,000 HK$ 3,950,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
2,000 lots 200,000 HK$ 7,900,000
3,000 lots 300,000 HK$ 11,850,000
4,000 lots 400,000 HK$ 15,800,000
5,000 lots 500,000 HK$ 19,750,000
6,000 lots 600,000 HK$ 23,700,000
7,000 lots 700,000 HK$ 27,650,000
8,000 lots 800,000 HK$ 31,600,000
9,000 lots 900,000 HK$ 35,550,000
10,000 lots 1,000,000 HK$ 39,500,000
20,000 lots 2,000,000 HK$ 79,000,000
30,000 lots 3,000,000 HK$ 118,500,000
40,000 lots 4,000,000 HK$ 158,000,000
50,000 lots 5,000,000 HK$ 197,500,000
58,268 lots 5,826,800 HK$ 230,158,600

Stock Connect Inclusion Analysis

HK Market Cap HK$ 8.51B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利约人民币335.8百万元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 2016201720182019-06
Revenue 1,634,2392,294,1182,908,1231,636,513
Cost of sales -1,136,333-1,519,653-1,960,073-1,114,088
Gross profit 497,906774,465948,050522,425
Other income and gains, net 39,03416,16453,75921,263
Selling and distribution expenses -32,038-47,163-54,647-28,766
Administrative expenses -252,328-345,773-420,456-241,463
Operating profit 229,931336,983479,442234,890
Net finance costs -21,377-68,536-82,366-42,399
Share of associates and JVs 00-1,132-5,798
Profit before tax 208,554268,447395,944186,693
Income tax expense -37,220-49,783-60,101-30,012
Profit for the year 171,334218,664335,843156,681
Profit attributable to owners 171,334222,497336,042161,323
Balance Sheet
Item 2016201720182019-06
Cash and cash equivalents 461,944293,601307,235331,324
Trade and bills receivables 352,048494,897603,993654,058
Inventories 42,84759,01570,14881,186
Total current assets 1,092,7441,070,8431,276,1071,604,706
Total assets 2,912,7714,143,6644,802,0795,347,325
Total current liabilities 678,098980,6541,308,0481,436,762
Total liabilities 1,153,1462,145,5602,475,5082,431,069
Total equity 1,759,6251,998,1042,326,5712,916,256
Equity attributable to owners 1,759,6251,985,4862,313,5802,833,898
Interest-bearing borrowings 668,4761,356,6621,433,9671,330,514
Cash Flow Statement
Item 2016201720182019-06
Net cash from operating activities 260,460594,138790,744252,315
Net cash from investing activities -1,139,082-1,279,911-714,599-502,067
Net cash from financing activities 1,256,275530,314-69,046278,194
Net increase in cash 377,653-155,4597,09928,442
Depreciation of PP&E 124,464186,171255,192148,216
Depreciation of right-of-use assets 24,92844,24658,02729,717
Amortisation of intangible assets 7082,2481,8891,378
Purchase of PP&E -962,058-874,100-523,609-303,386
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 42.25
First Day OpenHK$ 43.45
First Day Change6.96%
First Day Volume51976500.0
First Day Turnover2226200000.0
Use of Proceeds
1、約1,303.3百萬港元(或所得款項凈額約30%)將用于擴展中國實驗室及生產設施的產能及能力; 2、約434.4百萬港元(或所得款項凈額約10%)撥付美國及英國業務的進一步擴張; 3、約868.8百萬港元(或所得款項凈額約20%)將用于建立有關研發生物制劑的醫藥研發服務平臺; 4、約651.6百萬港元(或所得款項凈額約15%)將用于擴展臨床開發服務實力及能力; 5、約651.6百萬港元(或所得款項凈額約15%)將用于透過潛在收購在美國、歐洲、日本或中國提供醫藥研發服務且擁有尖端研發技術的合同研發服務及合同生產服務公司及/或其業務,來擴展我們的產能及/或能力; 6、約434.4百萬港元(或所得款項凈額約10%)將用于一般企業用途及用作營運資金。

Underwriting Syndicate

Joint Sponsors (3)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中信证券(香港)有限公司 CE AAK249 ORIENT CAPITAL (HONG KONG) LIMITED CE BDN128
Overall Coordinators (3)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CLSA LIMITED CE AAB893 ORIENT SECURITIES (HONG KONG) LIMITED CE AVD362
Joint Bookrunners (4)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CLSA LIMITED CE AAB893 ORIENT SECURITIES (HONG KONG) LIMITED CE AVD362 China Renaissance Securities (Hong Kong) Limited CE AZX839
Joint Lead Managers (3)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CLSA LIMITED CE AAB893 ORIENT SECURITIES (HONG KONG) LIMITED CE AVD362

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Athos Asia Event Driven Master Fund 195,809,400 HKD — 4.25% — 6 months 2020-05-28
2 Lake Bleu Prime Healthcare Master Fund Limited 313,298,200 HKD — 6.81% — 6 months 2020-05-28
3 Oaktree Funds 195,809,400 HKD — 4.25% — 6 months 2020-05-28
4 OrbiMed Funds 234,973,650 HKD — 5.10% — 6 months 2020-05-28
5 中国国有企业结构调整基金股份有限公司 313,298,200 HKD — 6.81% — 6 months 2020-05-28

Directors & Management

PositionChinese nameEnglish Name
Chairman樓柏良—
Company Secretary麥寶文—
No director data available.

Major Shareholders

Major Shareholders & Holdings樓博士、樓先生及鄭女士為一致行動人士,於全球發售前合共持有約28.56% A股;中信証券透過受控法團持有約28.29% A股;君聯資本系持股約18.49% A股。
About this page

This page shows Pharmaron (03759) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect